Former Vols guard Lofton underwent cancer treatment
Posted on Fri, May. 02, 2008
By BETH RUCKER
Associated Press Writer
Wade Payne, File / AP Photo
In this March 9, 2008 file photo, Tennessee's Chris Lofton (5) shoots over South Carolina's Brandis Raley-Ross during the second half of a college basketball game in Knoxville, Tenn. Lofton revealed to ESPN.com in a story posted Thursday, May 1, 2008, that he underwent surgery for testicular cancer in March 2007 and had four weeks of radiation starting in May.
KNOXVILLE, Tenn. --
Former Tennessee guard Chris Lofton underwent treatment for testicular cancer after a failed drug test revealed he potentially had a tumor.
Lofton revealed to ESPN.com that he underwent surgery in March 2007 and had four weeks of radiation starting in May.
Lofton was randomly picked during the 2007 NCAA tournament for a drug test that revealed he had high levels of a hormone that serves as an indicator of steroid use or cancer.
The Southeastern Conference's 3-point record holder said in a statement released Thursday that it was a difficult time for him but he's now cancer-free.
Coach Bruce Pearl said Lofton and his family had wanted to keep information about his cancer private throughout the season. Team officials declined to comment further about Lofton's condition, citing HIPPA medical privacy laws.
Lofton was The Associated Press' SEC player of the year as a junior and a second-team All-American. He was a preseason All-American going into his senior season.
Join the discussion
The Miami Herald is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from personal comments and remarks that are off point. In order to post comments, you must be a registered user of MiamiHerald.com. Your username will show along with the comments you post. Not a registered user? It's Free!
Register here. Thank you for taking the time to offer your thoughts.
